REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients
Por um escritor misterioso
Descrição
REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.
FDA Approves Rexulti for Treating Agitation Due to Alzheimer's
Story
FDA Approves First Drug Meant to Ease Alzheimer's-Linked Agitation
FDA advisors to weigh use of Rexulti for Alzheimer's agitation
Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for
Michael Okun on X: Brexpiprazole (Rexulti) approved by FDA for
FDA approves first drug to treat agitation symptoms associated
FDA Approves First Drug to Treat Dementia-Associated Agitation in
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA
FDA approves Lundbeck and Otsuka's agitation treatment for
de
por adulto (o preço varia de acordo com o tamanho do grupo)
